Skyhawk Therapeutics, Inc. is advancing SKY-0515 through a pivotal Phase 2/3 clinical trial aimed at addressing the unmet medical need in Huntington's Disease, a rare neurodegenerative disorder. The trial's design, which includes a randomized, double-blind, placebo-controlled approach, positions SKY-0515 as a potentially significant therapeutic option in a market with limited effective treatments. The estimated enrollment of 400 participants across multiple international sites indicates a robust commitment to data generation. Given the increasing prevalence of HD and the growing focus on neurodegenerative diseases, successful outcomes could lead to a strong market entry and competitive advantage, particularly if SKY-0515 demonstrates superior efficacy and safety profiles compared to existing therapies. Additionally, the trial's focus on pharmacodynamics and comprehensive efficacy measures enhances its potential attractiveness to investors and partners.